Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Julia X.C. Cao"'
Autor:
Liyun Ding, Julie S. Moyers, Julia X.C. Cao, Chen Zhang, M. Dodson Michael, Vladislav V. Kiselyov, Catherine Volk
Publikováno v:
Molecular and Cellular Endocrinology. 454:23-38
Background Basal insulin peglispro (BIL) is a novel, PEGylated insulin lispro that has a large hydrodynamic size compared with insulin lispro. It has a prolonged duration of action, which is related to a delay in insulin absorption and a reduction in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::356505404b6f2b8e7a6c8320fbce0d1b
https://doi.org/10.1016/j.mce.2017.05.032
https://doi.org/10.1016/j.mce.2017.05.032
Autor:
Timothy B. Durham, Jeffrey T. Dixon, James Lee Toth, Angela M. Siesky, Michael E. Christe, Valentine J. Klimkowski, Nathan A. Calvert, John F. Schindler, Dana Sindelar, Kyle W. Sloop, M. Dodson Michael, Jesline T. Alexander-Chacko, Julia X.C. Cao, Ginger Y. Wu, James E. McGee, Rachel N. Cavitt, Stefan Jon Thibodeaux, Sherry Y. Guo, Yong Wang, Michael J. Coghlan, Vladislav V. Kiselyov
Publikováno v:
Journal of Biological Chemistry. 290:20044-20059
Insulin-degrading enzyme (IDE, insulysin) is the best characterized catabolic enzyme implicated in proteolysis of insulin. Recently, a peptide inhibitor of IDE has been shown to affect levels of insulin, amylin, and glucagon in vivo. However, IDE(-/-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b79e6dcdb0455d21e4b543d83d06c40
https://doi.org/10.1074/jbc.m115.638205
https://doi.org/10.1074/jbc.m115.638205
Autor:
Angela M. Siesky, Eleftheria N. Finger, Kyle W. Sloop, Brett P. Monia, Armando R. Irizarry, Amy L. Cox, Robert Mckay, Sanjay Bhanot, Susan F. Murray, M. Dodson Michael, Hong Yan Zhang, Aaron D. Showalter, Sheri L. Booten, Julia X.C. Cao
Publikováno v:
Journal of Biological Chemistry. 282:19113-19121
d-Glucose-6-phosphatase is a key regulator of endogenous glucose production, and its inhibition may improve glucose control in type 2 diabetes. Herein, 2′-O-(2-methoxy)ethyl-modified phosphorothioate antisense oligonucleotides (ASOs) specific to th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09a463ab51cd5b31e1a6bac14f5db41f
https://doi.org/10.1074/jbc.m610759200
https://doi.org/10.1074/jbc.m610759200
Autor:
Amy L. Cox, Mark J. Tebbe, Kyle W. Sloop, Kathleen Valasek, Julia X.C. Cao, Michael J. Coghlan, M. Dodson Michael, Martin B. Brenner, Thomas B. Farb, Francis S. Willard, Aaron D. Showalter, James Ficorilli, Sonia Maria Gutierrez Sanfeliciano
Publikováno v:
Diabetes
OBJECTIVE The clinical effectiveness of parenterally-administered glucagon-like peptide-1 (GLP-1) mimetics to improve glucose control in patients suffering from type 2 diabetes strongly supports discovery pursuits aimed at identifying and developing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d89708c50fb324b9be311bec474f6ded
https://pubmed.ncbi.nlm.nih.gov/20823098
https://pubmed.ncbi.nlm.nih.gov/20823098